This highly innovative platform led by the Liverpool School of Tropical Medicine offers industry access to pioneering technologies which support the development of game-changing novel therapeutics.
A range of sophisticated technologies including innovative humanised tissue & microfluidic models, are available to industry to fast-track drug discovery. Any infection can be rapidly screened, and our repository of human tissue models enables more precise assessment of therapeutic impact and efficacy – helping to de-risk development and support innovation.
Organ-on-a-Chip (OOC) technology is transforming industry’s approach to drug development and precision medicine. In a pioneering development in infection R&D, iiCON provides access to OOC technology that enables companies to bypass in-vivo studies and connect multiple organs, creating holistic models that enable faster, more accurate drug development.
iiCON’s platform is establishing human 2D cell systems and 3D human spheroids/organoids infected with clinically relevant human pathogens. The screening platform will be capable of supporting pre-clinical investigation of human pathogens (including coinfections such as HIV/TB) within a human host environment. This will significantly improve translation of pre-clinical studies to clinical disease – creating a much-needed platform for the screening of virulent -intracellular pathogens.
This expedites the drug development journey and significantly de-risks late-stage clinical efficacy failures – creating a bridge to Controlled Human Infection Models (CHIM) and/or Phase I and Phase II clinical trials, accelerating product registration and commercialisation and introducing new drugs to market.
For more information or to learn how your business can engage with this platform.
Head of the Department of Tropical Disease Biology, Liverpool School of Tropical Medicine
Professor Biagini’s career has focused on the biochemistry, pharmacology and therapeutics of human pathogens most notably Plasmodium falciparum and Mycobacterium tuberculosis. He has over 20 years’ experience in molecular pharmacology and drug discovery/development from the development of HTS campaigns to candidate declaration working with Industry and with product development partnerships (PDPs).